The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
By MATT McCORD Using opioids to treat acute pain is a lot like burning coal to power our homes. Both are legacy solutions from an earlier era. Both were once celebrated as breakthroughs. And both have since proven to be dirty, dangerous, and incredibly costly to clean up. Despite this, we continue to rely on…
Nonprofit population health services company starts with internal customers but plans to expand
The growing use of AI chatbots for medical questions should not be seen as a threat to the healthcare system, but as a signal that patients aren’t trying to replace their physicians; they’re trying to find them. The post ChatGPT for Medical Use Is a Cry for Help. We Need Better Medical Triage appeared first…
This explainer answers key questions about mpox, the international response to date including the U.S. government’s role, and its challenges. It also discusses how the global emergency might affect the U.S. and the current status of mpox circulation within the U.S.
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. The post FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in…
Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers. The post Gilead Sciences Gains In Vivo Cell Therapy…
More than 40 million Americans live with migraine and other headache disorders. They include children trying to stay in school, workers trying to remain employed, parents caring for their families, veterans and first responders living with post-traumatic headache, and more. The post Headache Disorders Have Been Part of the American Story for 250 Years appeared…
It’s a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain. The post The MFN Executive Order: A Global Reset for U.S. Pharma appeared first on MedCity News.
Every life sciences organization needs to consider how best to apply machine learning (ML) to RWE to support better patient outcomes. Here’s how they can ensure RWE is “ML-ready.” The post Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation appeared first on MedCity News.